After finding that its two-dose vaccine did not produce the desired level of immunity in kids, the company decided to try a third shot.
- Pfizer’s “kid-sized” vaccine, which is already approved for children between five and eleven, does not “generate a strong enough immune response” in younger kids.
- Thus, the company now intends to add a third dose as part of its ongoing trials on children aged between six months and four years old.
COVID VACCINES FOR KIDS:
- Previously, CEO Albert Bourla said the company could have enough information on young kids by the end of this year. Yet due to the new study results, Pfizer will not have data to submit to regulators until the first half of 2022 at the earliest.
- In a press release, Pfizer announced that the two-dose vaccine produced an immune response in kids under age two, but not in children ages two to four.
- “The decision to evaluate a third dose for children 6 months to under 5 years of age reflects the companies’ commitment to carefully select the right dose to maximize the risk-benefit profile,” the company said.
- At the same time, American experts and foreign governments now sound the alarm on the Pfizer and Moderna vaccines’ potential side effects in young people.